AlphaMadera's AlphaVal page computes Keros Therapeutics, Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag KROS as undervalued, fairly valued, or overvalued.

What is Keros Therapeutics, Inc.'s fair value?

Fair value for KROS is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value KROS?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from KROS's most recent reported fundamentals.

KROS - Keros Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $102.60 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

AlphaVal Unavailable

AlphaVal: KROS intrinsic value ($122) is 11x the stock price ($11.26). Likely stale financials (post-split price with pre-split EPS), ADR currency mismatch, or bad data.